Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature

References

• Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clin Med. 2021;21(3):170–173. doi:10.7861/clinmed.2021-0257
   PubMed Web of Science ®Google Scholar
• Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk factors for the development of psoriasis. Int J Mol Sci. 2019;20(18):18. doi:10.3390/ijms20184347
   Web of Science ®Google Scholar
• Amin M, Lee EB, Tsai TF, Wu JJ. Psoriasis and co-morbidity. Acta Derm Venereol. 2020;100(3):adv00033. doi:10.2340/00015555-3387
   PubMed Web of Science ®Google Scholar
• Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840–848. doi:10.1111/bjd.18245
   PubMed Web of Science ®Google Scholar
• Kouris A, Platsidaki E, Kouskoukis C, Christodoulou C. Psychological parameters of psoriasis. Psychiatrike. 2017;28(1):54–59. doi:10.22365/jpsych.2017.281.54
   PubMedGoogle Scholar
• Camela E, Potestio L, Ruggiero A, Ocampo-Garza SS, Fabbrocini G, Megna M. Towards personalized medicine in psoriasis: current progress. Psoriasis. 2022;12:231–250. doi:10.2147/PTT.S328460
   PubMed Web of Science ®Google Scholar
• Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475. doi:10.3390/ijms20061475
   PubMed Web of Science ®Google Scholar
• Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris – part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461–2498. doi:10.1111/jdv.16915
   PubMed Web of Science ®Google Scholar
• Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris – part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021;35(2):281–317. doi:10.1111/jdv.16926
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Camela E, Potestio L, Fabbrocini G, Megna M. Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge. Expert Opin Drug Saf. 2022;21(12):1445–1451. doi:10.1080/14740338.2022.2160447
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Fabbrocini G, Camela E. Treating psoriasis in the elderly: biologics and small molecules. Expert Opin Biol Ther. 2022;1–18. doi:10.1080/14712598.2022.2089020
   Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Camela E, Fabbrocini G, Megna M. Bimekizumab for the treatment of psoriasis: a review of the current knowledge. Psoriasis. 2022;12:127–137. doi:10.2147/PTT.S367744
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Picone V, Martora F, Fabbrocini G, Megna M. Guselkumab, risankizumab, and tildrakizumab in the management of psoriasis: a review of the real-world evidence. Clin Cosmet Investig Dermatol. 2022;15:1649–1658. doi:10.2147/CCID.S364640
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Fabbrocini G, Cinelli E. Tildrakizumab: a new therapeutic option for erythrodermic psoriasis? Dermatol Ther. 2021;34(5):e15030. doi:10.1111/dth.15030
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Fabbrocini G, Ruggiero A. Long-term efficacy and safety of guselkumab for moderate to severe psoriasis: a 3-year real-life retrospective study. Psoriasis. 2022;12:205–212. doi:10.2147/PTT.S372262
   PubMed Web of Science ®Google Scholar
• Marasca C, Fornaro L, Martora F, Picone V, Fabbrocini G, Megna M. Onset of vitiligo in a psoriasis patient on ixekizumab. Dermatol Ther. 2021;34(5):e15102. doi:10.1111/dth.15102
   PubMed Web of Science ®Google Scholar
• Balogh EA, Bashyam AM, Ghamrawi RI, Feldman SR. Emerging systemic drugs in the treatment of plaque psoriasis. Expert Opin Emerg Drugs. 2020;25(2):89–100. doi:10.1080/14728214.2020.1745773
   PubMed Web of Science ®Google Scholar
• Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. 2015;151(9):961–969. doi:10.1001/jamadermatol.2015.0718
   PubMed Web of Science ®Google Scholar
• Catlett IM, Hu Y, Gao L, Banerjee S, Gordon K, Krueger JG. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. J Allergy Clin Immunol. 2022;149(6):2010–2020.e8. doi:10.1016/j.jaci.2021.11.001
   PubMed Web of Science ®Google Scholar
• Estevinho T, Lé AM, Torres T. Deucravacitinib in the treatment of psoriasis. J Dermatolog Treat. 2023;34(1):2154122. doi:10.1080/09546634.2022.2154122
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
   PubMed Web of Science ®Google Scholar
• Papp K, Gordon K, Thaçi D, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med. 2018;379(14):1313–1321. doi:10.1056/NEJMoa1806382
   PubMed Web of Science ®Google Scholar
• Thaçi D, Strober B, Gordon KB, et al. Deucravacitinib in moderate to severe psoriasis: clinical and quality-of-life outcomes in a phase 2 trial. Dermatol Ther. 2022;12(2):495–510. doi:10.1007/s13555-021-00649-y
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29–39. doi:10.1016/j.jaad.2022.07.002
   PubMed Web of Science ®Google Scholar
• Strober B, Thaçi D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program for evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023;88(1):40–51. doi:10.1016/j.jaad.2022.08.061
   PubMed Web of Science ®Google Scholar
• Bristol Myers Squibb. New two-year deucravacitinib data rein- force durable efficacy and consistent safety profile in treatment of moderate to severe plaque psoriasis [media release]; 2022. Available from: http://www.bms.com. Accessed May 2, 2023.
   Google Scholar
• Bristol Myers Squibb. Bristol Myers Squibb announces new SotyktuTM (deucravacitinib) long-term data showing clinical efficacy maintained for up to two years with continuous treat- ment in moderate-to-severe plaque psoriasis [media release]; 2022. h.
   Google Scholar
• Efficacy and safety of deucravacitinib versus placebo in participants with moderate-to-severe scalp psoriasis. Available from: https://clinicaltrials.gov/ct2/show/NCT05478499?cond=deucravacitinib+psoriasis&draw=2&rank=2. Accessed February 19, 2023.
   Google Scholar
• Deucravacitinib for the treatment of palmoplantar pustulosis. Available from: https://clinicaltrials.gov/ct2/show/NCT05710185?cond=deucravacitinib+psoriasis&draw=2&rank=8. Accessed February 19, 2023.
   Google Scholar
• An investigator initiated open label study evaluating the efficacy and tolerability of oral deucravacitinib for the treatment of nail psoriasis. Available from: https://clinicaltrials.gov/ct2/show/NCT05124080?cond=deucravacitinib+psoriasis&draw=2&rank=5.Ac. Accessed May 2, 2023.
   Google Scholar
• A study to evaluate the drug levels, efficacy and safety of deucravacitinib in pediatric participants with moderate to severe plaque psoriasis. Available from: https://clinicaltrials.gov/ct2/show/NCT04772079?cond=deucravacitinib+psoriasis&draw=2&rank=4.Acc. Accessed May 2, 2023.
   Google Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert Opin Drug Saf. 2023:1–17. doi:10.1080/14740338.2023.2173170
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert Opin Drug Saf. 2023:1–16. doi:10.1080/14740338.2023.2173171
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Ruggiero A, Camela E, Fabbrocini G. Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study. J Dermatolog Treat. 2022;1–18. doi:10.1080/09546634.2022.2036674
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Ruggiero A, Camela E, Fabbrocini G. Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study. Dermatol Ther. 2022;35(7):e15524. doi:10.1111/dth.15524
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Camela E, Fabbrocini G, Ruggiero A. Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: results from an Italian single-center retrospective study in a real-life setting. Dermatol Ther. 2022;35(9):e15667. doi:10.1111/dth.15667
   PubMed Web of Science ®Google Scholar
• Marasca C, Annunziata MC, Camela E, et al. Teledermatology and inflammatory skin conditions during COVID-19 era: new perspectives and applications. J Clin Med. 2022;11(6):1511. doi:10.3390/jcm11061511
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Martora F, Fabbrocini G, et al. The role of teledermatology during the COVID-19 pandemic: a narrative review. Clin Cosmet Investig Dermatol. 2022;15:2785–2793. doi:10.2147/CCID.S377029
   PubMed Web of Science ®Google Scholar
• De Lucia M, Potestio L, Costanzo L, Fabbrocini G, Gallo L. Scabies outbreak during COVID-19: an Italian experience. Int J Dermatol. 2021;60(10):1307–1308. doi:10.1111/ijd.15809
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Villani A, Tajani A, Fabbrocini G, Potestio L. Teledermatology: a useful tool also after COVID-19 era? J Cosmet Dermatol. 2022;21(6):2309–2310. doi:10.1111/jocd.14938
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Martora F, Picone V, et al. The impact of COVID-19 infection on patients with psoriasis treated with biologics: an Italian experience. Clin Exp Dermatol. 2022;47(12):2280–2282. doi:10.1111/ced.15336
   PubMed Web of Science ®Google Scholar
• Nassim D, Alajmi A, Jfri A, Pehr K. Apremilast in dermatology: a review of literature. Dermatol Ther. 2020;33(6):e14261. doi:10.1111/dth.14261
   PubMed Web of Science ®Google Scholar
• Krueger JG, McInnes IB, Blauvelt A. Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. J Am Acad Dermatol. 2022;86(1):148–157. doi:10.1016/j.jaad.2021.06.869
   PubMed Web of Science ®Google Scholar
• Burke JR, Cheng L, Gillooly KM, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med. 2019;11(502):502. doi:10.1126/scitranslmed.aaw1736
   Web of Science ®Google Scholar
• FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requ. Accessed May 2, 2023.
   Google Scholar
• Nogueira M, Puig L, Torres T. JAK inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors. Drugs. 2020;80(4):341–352. doi:10.1007/s40265-020-01261-8
   PubMed Web of Science ®Google Scholar
• SOTYKTU US. Prescribing information. Available from: https://packageinserts.bms.com/pi/pi_sotyktu.pdf. Accessed February 19, 2023.
   Google Scholar
• Camela E, Potestio L, Fabbrocini G, Ruggiero A, Megna M. New frontiers in personalized medicine in psoriasis. Expert Opin Biol Ther. 2022;1–3. doi:10.1080/14712598.2022.2113872
   Web of Science ®Google Scholar